Influence of transfusion of lymphokine-activated T killer cells on inflammatory responses in dogs after laparotomy

Abstract

The influence of transfusion of lymphokine-activated T killer cells (T-LAK) on inflammatory responses was examined in dogs after laparotomy. Plasma C-reactive protein (CRP) level, cell numbers of peripheral blood lymphocytes (PBLs) and T lymphocyte subsets (CD3+, CD4+ and CD8+) and mRNA expression levels of cytokines including interleukin (IL)-2, IL-12, IL-4, IL-10 and transforming growth factor (TGF)-β in peripheral blood mononuclear cells (PBMCs) were measured in dogs with (T-LAK group) or without (control group) a single T-LAK administration immediately after laparotomy. The plasma CRP level initially increased and then decreased to the normal range at 7 days after laparotomy in the T-LAK group, which was earlier than in the control group. The expression level of IL-10 mRNA showed a marked postoperative increase and was significantly higher than the preoperative level on day 7 (P<0.05), whereas the level in the control group showed no clear change after laparotomy. A significant increase in IL-2 mRNA expression level in the T-LAK group was observed on day 14, which was two weeks earlier than in the control group (P<0.05). These results suggest that T-LAK therapy in dogs after laparotomy leads to earlier resolution of postoperative inflammation by production of an anti-inflammatory cytokine (IL-10) in the early phase of the postoperative period and earlier restoration of cell-mediated immunity related to cytokine production by PBMCs.

The effect of an ex vivo boosted immune cell therapy on canine atopic dermatitis: an open, uncontrolled pilot study

“…CD8+ cells were predominant among the activated lymphocytes, and a significantly increased number of IFN‐γ‐producing cells were observed. These results are consistent with those obtained in previous studies …”

“…The isolation, culture and expansion of immune cells were performed with modifications according to procedures reported in previous studies . Two weeks before starting EBIC therapy, 10 mL of the dog's own peripheral blood was collected in vacuum tubes coated with heparin (BD Vacutainer ® , Becton Dickinson; Franklin Lakes, NJ, USA).…”

“…In ex vivo culture, the characteristics of EBICs are comparable to those of PBMCs in that (1) the CD8 + T cells increase in proportion and predominate, and (2) the proportion of IFN‐γ‐producing cells increases significantly. Transfusion of activated canine lymphocytes has been reported to reinforce the recipient's immune response and increases the recipient's serum interferon‐gamma (IFN‐γ) concentration . IFN‐γ, interleukin (IL)‐4, IL‐10 and IL‐31 have been reported to play important roles in dogs with AD .…”

A case of ex vivo boosted immune cell therapy for chronic ulcerative dermatitis in a dog

“…Interleukin-2 (IL-2) was used as a mitogen for lymphocyte activation. The isolation, culture, and expansion procedures for immune cells were obtained and modified from previous studies (7,8). The phenotypes of cells before and after processing were analyzed by flow cytometry, and the outcomes are presented in Figure 2.…”

“…In humans, this immunotherapy is commonly used to treat cancer patients (6). In dogs, several studies on T-LAK have been conducted and demonstrated reinforcement of the recipient's immunity with this therapy (7,8).…”